诺司替勃 | 13583-21-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 诺司替勃
• 英文名称: norclostebol
• 英文别名: 4-Chlor-17β-hydroxy-oestr-4-en-3-on；4-Chlor-17β-hydroxy-estr-4-en-3-on；4-Chor-17β-hydroxyoestr-4-en-3-on；4-Chlor-19-nor-testosteron；(8R,9S,10R,13S,14S,17S)-4-chloro-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
• CAS: 13583-21-6
• 化学式: C₁₈H₂₅ClO₂
• 分子量: 308.848
• InChiKey: OZDDFAQVVGFDJP-YGRHGMIBSA-N

物化性质

• 熔点：
  220-223 °C
• 沸点：
  449.8±45.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)
• 溶解度：
  乙腈（少量溶解）、氯仿（少量溶解）、DMSO（少量溶解）、甲醇（少量溶解）

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  诺司替勃 在 potassium tert-butylate 作用下， 以 叔丁醇 为溶剂， 生成 4-羟基诺龙
  参考文献：
  名称：

  Camerino,B. et al., Gazzetta Chimica Italiana, 1962, vol. 92, p. 693 - 708

  摘要：

  DOI：
• 作为产物：
  描述：

  诺龙 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 诺司替勃
  参考文献：
  名称：

  甾类咪唑-1-羧酸酯。

  摘要：

  DOI：

  10.1021/jm00249a018

文献信息

• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2017023679A1

  公开（公告）日：2017-02-09

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在某些实施例中提供了一些符合本文所定义的A式化合物，其调节5-HT2C受体的活性。在某些实施例中还提供了一些方法，例如用于体重管理、诱导饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理性赌博、奖赏缺乏综合征和性成瘾，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱），尿失禁，精神障碍（包括精神分裂症、厌食症和暴食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森病和抗精神病药物引起的运动障碍），高血压，血脂异常，非酒精性脂肪肝病，肥胖相关肾脏疾病和睡眠呼吸暂停症。
• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DU RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2015066344A1

  公开（公告）日：2015-05-07

  Provided are 5-HT2C receptor agonists. Also provided are methods for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea. Also provided are compositions comprising a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent, and methods for reducing the frequency of smoking tobacco in an individual attempting to reduce frequency of smoking tobacco; aiding in the cessation or lessening of use of a tobacco product in an individual attempting to cease or lessen use of a tobacco product; aiding in smoking cessation and preventing associated weight gain; controlling weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; reducing weight gain associated with smoking cessation by an individual attempting to cease smoking tobacco; treating nicotine dependency, addiction and/or withdrawal in an individual attempting to treat nicotine dependency, addiction and/or withdrawal; or reducing the likelihood of relapse use of nicotine by an individual attempting to cease nicotine use comprising administering a selective 5-HT2C receptor agonist, optionally in combination with a supplemental agent.

  提供了5-HT2C受体激动剂。还提供了用于体重管理、诱导饱腹感、减少食物摄入量、预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病态赌博、奖赏缺乏综合征和性成瘾）、强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲）、睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱）、尿失禁、精神障碍（包括精神分裂症、厌食症和暴食症）、阿尔茨海默病、性功能障碍、勃起功能障碍、癫痫、运动障碍（包括帕金森病和抗精神病药物引起的运动障碍）、高血压、血脂异常、非酒精性脂肪肝病、肥胖相关肾脏疾病和睡眠呼吸暂停。还提供了包含选择性5-HT2C受体激动剂的组合物，可选地与辅助剂结合，以及用于减少个体尝试减少吸烟频率的吸烟频率；帮助个体戒除或减少使用烟草制品的个体戒除或减少使用烟草制品；帮助戒烟并预防相关体重增加；通过个体尝试戒烟来控制与戒烟相关的体重增加；通过个体尝试戒烟来减少与戒烟相关的体重增加；治疗尼古丁依赖、成瘾和/或戒断的个体尝试治疗尼古丁依赖、成瘾和/或戒断；或减少个体尝试戒除尼古丁使用的复发可能性，包括给予选择性5-HT2C受体激动剂，可选地与辅助剂结合。
• Somatostatin antagonists and agonists
  申请人：——

  公开号：US20020091090A1

  公开（公告）日：2002-07-11

  Compounds according to the formula A-B-Z-W, wherein A is selected from (C 6 -C 10 )aryl-, or (C 1 -C 9 )heteroaryl-, which groups may be optionally substituted; B is selected from (a) O, NH, NR 10 , —(CH 2 ) k —O—, —(CH 2 ) k —N—, and —(CH 2 ) k —NR 10 —, where R 10 is (C 1 -C 6 )alkyl and where k is 1 to 6 in each case, or 1 where said group (i) through (iv) is optionally substituted by 1 to 4, preferably 1 to 2, groups selected from (C 1 -C 6 )alkyl, halo, and (C 1 -C 6 )alkyl optionally substituted by 1 to 3 halo atoms wherein one of carbon atoms C 1 , C 2 , C 3 and C 4 of said piperidine or piperazine group is optionally replaced by a carbonyl group; Z and W are as herein described; and pharmaceutically acceptable salts, solvates or hydrates thereof; pharmaceutical compositions thereof; and methods useful to facilitate secretion of growth hormone(GH) in mammels.

  根据公式A-B-Z-W，其中 A选自(C6-C10)芳基或(C1-C9)杂环芳基，这些基团可以选择性地被取代； B选自 (a) O、NH、NR10、—(CH2)k—O—、—( )k—N—和—( )k—NR10—，其中R10为(C1-C6)烷基，k在每种情况下为1至6，或 1所述的该组(i)至(iv)可以选择性地被1至4个，优选1至2个，选自(C1-C6)烷基、卤素和(C1-C6)烷基，该烷基可以选择性地被1至3个卤原子取代，其中所述哌啶或哌嗪基团的碳原子C1、C2、C3和C4中的一个可以选择性地被羰基取代； Z和W如本文所述；以及其药学上可接受的盐、溶剂化合物或水合物；其制药组合物；以及用于促进哺乳动物分泌生长激素(GH)的方法。
• Gas chromatography/chemical ionization triple quadrupole mass spectrometry analysis of anabolic steroids: ionization and collision-induced dissociation behavior
  作者：Michael Polet、Wim Van Gansbeke、Peter Van Eenoo、Koen Deventer

  DOI：10.1002/rcm.7472

  日期：2016.2.28

  detection of new anabolic steroid metabolites and new designer steroids is a challenging task in doping analysis. Switching from electron ionization gas chromatography triple quadrupole mass spectrometry (GC/EI‐MS/MS) to chemical ionization (CI) has proven to be an efficient way to increase the sensitivity of GC/MS/MS analyses and facilitate the detection of anabolic steroids. CI also extends the possibilities

  新的合成代谢类固醇代谢物和新设计的类固醇的检测在掺杂分析中是一项艰巨的任务。从电子电离气相色谱三重四极杆质谱（GC / EI-MS / MS）切换到化学电离（CI）是提高GC / MS / MS分析灵敏度并促进合成代谢类固醇检测的有效方法。CI还扩展了GC / MS / MS分析的可能性，因为分子离子由于较软的电离而保留为其质子化形式。在EI中，由于分子离子的丰度低或不存在以及广泛的（很大程度上是不可预测的）碎片，很难找到以前未知但预期的代谢物。这项工作的主要目的是研究大量合成代谢雄激素类固醇（AAS）作为其三甲基甲硅烷基衍生物的CI和碰撞诱导解离（CID）行为，以确定结构与CID片段化之间的相关性。需要澄清这些相关性，以阐明未知类固醇和新代谢产物的结构。
• FLUORESCENCE BASED DETECTION OF SUBSTANCES
  申请人：Russell David

  公开号：US20090230322A1

  公开（公告）日：2009-09-17

  A method for the fluorescent detection of a substance, the method comprising providing particles comprising a metal or a metal oxide core, wherein one or more optionally fluorescently tagged antibodies or human specific peptide nucleic acid (PNA) oligomers for binding to a substance is/are bound, directly or indirectly, to the surface of the metal or metal oxide; contacting a substrate, which may or may not have the substance on its surface, with the particles for a time sufficient to allow the antibody/PNA oligomer to bind with the substance; removing those particles which have not bound to the substrate; if the antibodies or PNA oligomers are not fluorescently tagged, contacting the substrate with one or more fluorophores that selectively bind with the antibody and/or substance, then optionally washing the substrate to remove unbound fluorophores; and illuminating the substrate with appropriate radiation to show the fluorophores on the substrate.

  一种用于荧光检测物质的方法，该方法包括提供含有金属或金属氧化核的颗粒，其中一种或多种可选择性地荧光标记的抗体或人特异性肽核酸（PNA）寡聚体，用于结合到物质上，直接或间接地结合到金属或金属氧化物的表面；将可能在其表面具有或不具有该物质的基质与这些颗粒接触一段时间，以充分允许抗体/PNA寡聚体与该物质结合；移除那些未与基质结合的颗粒；如果抗体或PNA寡聚体未被荧光标记，则将基质与一种或多种能特异性结合抗体和/或物质的荧光剂接触，然后可选择地清洗基质以去除未结合的荧光剂；并用适当的辐射照射基质以显示基质上的荧光剂。